Eileen Sawyer

Eileen Sawyer

Company: uniQure, Inc

Job title: Vice President, Global Medical Affairs

Bio:

Eileen Sawyer joined uniQure in 2016, where she serves as Vice President and Head of Medical Affairs, leading uniQure’s medical affairs activities across the portfolio with a focus on supporting the hemophilia B gene therapy program. Prior to joining uniQure, she spent 3 years at Alexion Pharmaceuticals where she served as the scientific communications lead for the launch of asfotase alfa (Strensiq), an enzyme replacement for a rare metabolic disease. Eileen earned her PhD in Neuroscience from Emory University in 2011 and conducted her post-doctoral training in preclinical drug discovery at Harvard University prior to transitioning to industry.

Seminars:

Live Presenter Q&A 10:10 am

Read more

day: Day One

A Patient-Centric Approach to Drug Development Across the Lifecycle 8:50 am

• Incorporating patient perspectives and how to involve patients in gene therapy drug development • At what stage of the program lifecycle should patients be involved in order to meet their needs and to optimize trial conduct • How to provide a compelling value proposition for multiple stakeholdersRead more

day: Day One

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.